Iron accumulation in the basal ganglia in Huntington's disease: Cross-sectional data from the IMAGE-HD study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 5, 2016, Pages 545-549

  Domínguez D, Juan F ^a   Ng, Amanda C L ^b   Poudel, Govinda ^a,c   Stout, Julie C ^a   Churchyard, Andrew ^d   Chua, Phyllis ^a   Egan, Gary F ^a   Georgiou Karistianis, Nellie ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Life Sciences Computation Centre   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BASAL GANGLION; BIOACCUMULATION; BRAIN LEVEL; CAUDATE NUCLEUS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; GLOBUS PALLIDUS; HUMAN; HUNTINGTON CHOREA; IMAGE ANALYSIS; IMAGE PROCESSING; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE SUSCEPTIBILITY MAPPING; SUSCEPTIBILITY WEIGHTED IMAGING; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; NEUROIMAGING; SEVERITY OF ILLNESS INDEX;

IRON;

ADULT; BASAL GANGLIA; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HUNTINGTON DISEASE; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROIMAGING; SEVERITY OF ILLNESS INDEX;

EID: 84930532225     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-310183     Document Type: Article

References (43)

1. Berg D, Youdim MB. Role of iron in neurodegenerative disorders. Top Magn Reson Imaging 2006;17:5-17.
2. Bartzokis G, Cummings J, Perlman S, et al. Increased basal ganglia iron levels in Huntington disease. Arch Neurol 1999;56:569-74.
3. Bartzokis G, Lu PH, Tishler TA, et al. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res 2007;32:1655-64.
4. Browne SE, Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 2006;8:2061-73.
5. Dexter DT, Jenner P, Schapira AH, et al. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992;32(Suppl):S94-100.
6. Vymazal J, Klempir J, Jech R, et al. MR relaxometry in Huntington's disease: correlation between imaging, genetic and clinical parameters. J Neurol Sci 2007;263:20-5.
7. Sánchez-Castañeda C, Cherubini A, Elifani F, et al. Seeking Huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. Hum Brain Mapp 2013;34:1625-35.
8. Rosas HD, Chen YI, Doros G, et al. Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Arch Neurol 2012;69:887-93.
9. Dumas EM, Versluis MJ, van den Bogaard SJ, et al, TRACK-HD investigators. Elevated brain iron is independent from atrophy in Huntington's disease. Neuroimage 2012;61:558-64.
10. Jurgens CK, Jasinschi R, Ekin A, et al. MRI T2 hypointensities in basal ganglia of premanifest Huntington's disease. PLoS Curr 2010;2:pii: RRN1173.
11. Di Paola M, Phillips OR, Sanchez-Castaneda C, et al. MRI measures of corpus callosum iron and myelin in early Huntington's disease. Hum Brain Mapp 2014;35:3143-51.
12. Sánchez-Castañeda C, Squitieri F, Di Paola M, et al. The role of iron in gray matter degeneration in Huntington's disease: a magnetic resonance imaging study. Hum Brain Mapp 2015;36:50-66.
13. Langkammer C, Krebs N, Goessler W, et al. Susceptibility induced gray-white matter MRI contrast in the human brain. Neuroimage 2012;59:1413-19.
14. Deistung A, Schafer A, Schweser F, et al. Toward in vivo histology: a comparison of quantitative susceptibility mapping (QSM) with magnitude-, phase-, and R2∗-imaging at ultra-high magnetic field strength. Neuroimage 2013;65:299-314.
15. de Rochefort L, Liu T, Kressler B, et al. Quantitative susceptibility map reconstruction from MR phase data using Bayesian regularization: validation and application to brain imaging. Magn Reson Med 2010;63:194-206.
16. Lim IA, Faria AV, Li X, et al. Human brain atlas for automated region of interest selection in quantitative susceptibility mapping: application to determine iron content in deep gray matter structures. Neuroimage 2013;82:449-69.
17. Wharton S, Bowtell R. Whole-brain susceptibility mapping at high field: a comparison of multiple- and single-orientation methods. Neuroimage 2010;53:515-25.
18. Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med 2013;368:1169-71.
19. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801.
20. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem 1958;3:41-51.
21. Georgiou-Karistianis N, Gray MA, Domínguez D JF, et al. Automated differentiation of pre-diagnosis Huntington's disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: the IMAGE-HD study. Neurobiol Dis 2013;51:82-92.
22. Domínguez D JF, Egan GF, Gray MA, et al. Multi-modal neuroimaging in premanifest and early Huntington's disease: 18 month longitudinal data from the IMAGE-HD study. PLoS ONE 2013;8:e74131.
23. Georgiou-Karistianis N, Poudel GR, Domínguez D JF, et al. Functional and connectivity changes during working memory in Huntington's disease: 18 month longitudinal data from the IMAGE-HD study. Brain Cogn 2013;83:80-91.
24. Georgiou-Karistianis N, Stout JC, Domínguez D JF, et al. Functional magnetic resonance imaging of working memory in Huntington's disease: cross-sectional data from the IMAGE-HD study. Hum Brain Mapp 2014;35:1847-64..
25. Poudel GR, Stout JC, Domínguez DJ, et al. White matter connectivity reflects clinical and cognitive status in Huntington's disease. Neurobiol Dis 2014;65C:180-7.
26. Poudel GR, Stout JC, Gray MA, et al. Functional changes during working memory in Huntington's disease: 30 month longitudinal data from the IMAGE-HD study. Brain Struct Funct 2015;220:501-12.
27. Poudel GR, Egan GF, Churchyard A, et al. Abnormal synchrony of resting state networks in premanifest and symptomatic Huntington disease: the IMAGE-HD study. J Psychiatry Neurosci 2014;39:87-96.
28. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11:136-42.
29. Langbehn DR, Brinkman RR, Falush D, et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004;65:267-77.
30. Schofield MA, Zhu Y. Fast phase unwrapping algorithm for interferometric applications. Opt Lett 2003;28:1194-6.
31. Wu B, Li W, Guidon A, et al. Whole brain susceptibility mapping using compressed sensing. Magn Reson Med 2012;67:137-47.
32. Li W, Wu B, Liu C. Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition. Neuroimage 2011;55:1645-56.
33. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP, 2011.
34. Langkammer C, Krebs N, Goessler W, et al. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 2010;257:455-62.
35. Bilgic B, Pfefferbaum A, Rohlfing T, et al. MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 2012;59:2625-35.
36. Rivera-Mancia S, Perez-Neri I, Rios C, et al. The transition metals copper and iron in neurodegenerative diseases. Chem Biol Interact 2010;186:184-99.
37. Douaud G, Behrens TE, Poupon C, et al. In vivo evidence for the selective subcortical degeneration in Huntington's disease. Neuroimage 2009;46:958-66.
38. Robinson S, Grabner G, Witoszynskyj S, et al. Combining phase images from multi-channel RF coils using 3D phase offset maps derived from a dual-echo scan. Magn Reson Med 2011;65:1638-48.
39. Li W, Wu B, Batrachenko A, et al. Differential developmental trajectories of magnetic susceptibility in human brain gray and white matter over the lifespan. Hum Brain Mapp 2014;35:2698-713.
40. Langkammer C, Liu T, Khalil M, et al. Quantitative susceptibility mapping in multiple sclerosis. Radiology 2013;267:551-9.
41. Mounsey RB, Teismann P. Chelators in the treatment of iron accumulation in Parkinson's disease. Int J Cell Biol 2012;2012:983245.
42. Devos D, Moreau C, Devedjian JC, et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 2014;21:195-210.
43. Wilson RB. Therapeutic developments in Friedreich ataxia. J Child Neurol 2012;27:1212-16.